Research programme: neurological injury therapeutics - PresSura Neuro

Drug Profile

Research programme: neurological injury therapeutics - PresSura Neuro

Alternative Names: EU-C-002

Latest Information Update: 07 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer PresSura Neuro
  • Class
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Craniocerebral trauma; Reperfusion injury

Most Recent Events

  • 03 Apr 2017 Research programme: neurological injury therapeutics is still in preclinical development for Reperfusion-injury (Prevention, followed by stroke), Craniocerebral-trauma and Brain injuries in Australia (PresSura Neuro website, April 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Craniocerebral-trauma in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Reperfusion-injury(Prevention) in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top